City Therapeutics
City Therapeutics develops RNA-interference therapeutics and an engineering platform across disease areas.
$99.5MSeries B
Role not disclosedActivity from announced rounds
City Therapeutics develops RNA-interference therapeutics and an engineering platform across disease areas.
Develops autonomous robotic phlebotomy devices for diagnostic blood collection